Document is current
Any future updates will be listed below
-
Authors
Halling, Christine Marie Bækø https://orcid.org/0000-0003-3899-4517
Møller, Morten Hylander https://orcid.org/0000-0002-6378-9673
Marker, Søren https://orcid.org/0000-0003-3602-4541
Krag, Mette https://orcid.org/0000-0002-5246-8727
Kjellberg, Jakob https://orcid.org/0000-0003-4336-2397
Perner, Anders https://orcid.org/0000-0002-4668-0123
Gyrd-Hansen, Dorte https://orcid.org/0000-0003-1137-2304
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02467621 at ClinicalTrials.govDocuments that mention this clinical trial
The effects of pantoprazole vs. placebo on 1-year outcomes, resource use and employment status in ICU patients at risk for gastrointestinal bleeding: a secondary analysis of the SUP-ICU trial
https://doi.org/10.1007/s00134-022-06631-2
Heterogeneity of treatment effect of prophylactic pantoprazole in adult ICU patients: a post hoc analysis of the SUP-ICU trial
https://doi.org/10.1007/s00134-019-05903-8
-
Funding
Funding for this research was provided by:
Innovationsfonden (4108-00011A)
Rigshospitalet
Region Hovedstaden
the Regions of Denmark
the Scandinavian Society of Anaesthesiology and Intensive Care Medicine
Grosserer Jakob Ehrenreich og Hustru Grethe Ehrenreichs Fond
Aase og Ejnar Danielsens Fond
Danish Society of Anaesthesiology and Intensive Care Medicine
Lægeforeningen
European Society of Intensive Care Medicine
- License Information
-
More Information
Article History
Received: 30 August 2021
Accepted: 16 January 2022
First Online: 5 February 2022
Declarations
:
: The terms of this research project have been reviewed and approved by the Danish Center for Social Science Research (VIVE) in accordance with its policy on objectivity and independence in research. VIVE is an independent national research centre working within the major welfare fields and affiliated with the Ministry of Economic Affairs and the Interior. The Department of Intensive Care, Rigshospitalet receives support for research from the Novo Nordisk Foundation, Sygeforsikringen ‘Danmark’, Fresenius Kabi and Pfizer.
: The trial is registered at Clinicaltrials.gov Identifier: NCT02467621. The study obtained ethics approval from The National Committee on Health Research Ethics, Denmark (H-15003141), and The Danish Data Protection Agency (2012-58-0004, RH-2015-32, I-Suite no: 03695) issued approval for the SUP-ICU trial. Further, the Danish Health and Medicine Authority (journal number: 2015030166) and the Danish Medicine Agency (journal number: 2015110369) issued approval for the trial. EudraCT-identifier: 2015-000318-24.
: Written informed consent was obtained from the patients or their legal surrogates in accordance with national regulations.
: Not applicable.
